News

09 June 2022

Proveca enters an exclusive agreement with Mawdsley Brooks Brazil

Proveca has entered an exclusive agreement with Mawdsley Brooks Brazil, part of global pharmaceutical services provider Mawdsleys, to commercialise and distribute Sialanar® in Brazil.

Under the terms of the agreement, Mawdsley Brooks Brazil will have exclusive rights to market and distribute Sialanar® in Brazil. It is estimated that approximately 13,000 children with neurodisabilities suffer from sialorrhoea in the country today.

Sialanar® (320 mcg/ml glycopyrronium, oral solution) received a European Paediatric Use Marketing Authorisation (PUMA) on 15th September 2016 for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.

Dr Simon Bryson, CEO and founder of Proveca Ltd, commented “We are delighted to announce this agreement with Mawdsley Brooks Brazil to make Sialanar® available to children with neurodisabilities who suffer from sialorrhoea. As in many countries across the world there is a high unmet need to manage this condition and improve the quality of the lives of patients and their carers. We are looking forward to working with Mawdsley Brooks Brazil who can offer their first-class capabilities to support the launch of Sialanar® in Brazil. This is another significant agreement outside the EU for Sialanar as part of our commercialisation strategy to optimise access of our products across the world.”

William Sanders, Group CEO of Mawdsleys Group commented “This is an exciting opportunity for Mawdsley Brooks Brazil to in-license another specialty care medicine into its portfolio. Once commercialised, we believe that Sialanar® will give an important new treatment option for paediatric patients with sialorrhea in Brazil. We look forward to creating access to this new medicine in Brazil through our in-country regulatory, distribution and market access capabilities and to working closely with Proveca on other such projects in the future.”

From our portfolio

Bitrobius Genetics

Biotechnology

viewview our portfolio

Our Team

Natalie Melvin

view complete team

Contact us

Tel: 01625 344300

email